Michael A. Metzger

Insider Reports History

Reporting-owner location: Waltham, MA
Latest reporting-owner signature: /s/ Michael A. Metzger
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Michael A. Metzger

Form 4 holding Chief Executive Officer, Director

Syndax Pharmaceuticals Inc

Security class: Common Stock
Shares / value: 484,843
Estimated value: $11,752,691
Report date: 08 Jul 2026
Price: $24.24
Ownership: Direct

Form 4 holding Chief Executive Officer, Director

Syndax Pharmaceuticals Inc

Security class: Stock Options (Right to buy)
Shares / value: 440,000
Estimated value: $8,989,200
Report date: 04 Feb 2026
Price: $20.43
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

Pyxis Oncology, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 45,867
Estimated value: $36,239
Report date: 24 Mar 2026
Price: $0.9800
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

CTI BIOPHARMA CORP

Security class: Stock Option (Right to Buy)
Shares / value: 0
Estimated value
Report date: 26 Jun 2023
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Chief Executive Officer, Director

Syndax Pharmaceuticals Inc

Security class: Stock Option (Right to buy)
Shares / value: 0
Estimated value
Report date: 08 Jul 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Michael A. Metzger

4 SNDX

Syndax Pharmaceuticals Inc

Report period: 08 Jul 2026
Transactions: 3
Transaction value: -$784,776
Accepted by SEC: 09 Jul 2026, 16:54
Role: Chief Executive Officer, Director
Next action: Open filing details

4 SNDX

Syndax Pharmaceuticals Inc

Report period: 01 Jun 2026
Transactions: 1
Transaction value: -$130,025
Accepted by SEC: 02 Jun 2026, 16:30
Role: Chief Executive Officer, Director
Next action: Open filing details

4 PYXS

Pyxis Oncology, Inc.

Report period: 24 Mar 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 25 Mar 2026, 17:09
Role: Director
Next action: Open filing details

4 SNDX

Syndax Pharmaceuticals Inc

Report period: 09 Feb 2026
Transactions: 1
Transaction value: -$360,819
Accepted by SEC: 10 Feb 2026, 09:00
Role: Chief Executive Officer, Director
Next action: Open filing details

4 SNDX

Syndax Pharmaceuticals Inc

Report period: 04 Feb 2026
Transactions: 4
Transaction value: +$8,836,365
Accepted by SEC: 06 Feb 2026, 17:54
Role: Chief Executive Officer, Director
Next action: Open filing details

4 SNDX

Syndax Pharmaceuticals Inc

Report period: 08 Sep 2025
Transactions: 3
Transaction value: -$867,375
Accepted by SEC: 08 Sep 2025, 18:45
Role: Chief Executive Officer, Director
Next action: Open filing details

4 SNDX

Syndax Pharmaceuticals Inc

Report period: 16 Jul 2025
Transactions: 1
Transaction value: -$69,953
Accepted by SEC: 18 Jul 2025, 16:30
Role: Chief Executive Officer, Director
Next action: Open filing details

4 PYXS

Pyxis Oncology, Inc.

Report period: 31 Mar 2025
Transactions: 1
Transaction value: +$36,239
Accepted by SEC: 02 Apr 2025, 09:05
Role: Director
Next action: Open filing details

4 SNDX

Syndax Pharmaceuticals Inc

Report period: 14 Mar 2025
Transactions: 2
Transaction value: +$43,733
Accepted by SEC: 17 Mar 2025, 06:01
Role: Chief Executive Officer, Director
Next action: Open filing details

4 SNDX

Syndax Pharmaceuticals Inc

Report period: 04 Mar 2025
Transactions: 3
Transaction value: -$61,303
Accepted by SEC: 06 Mar 2025, 16:10
Role: Chief Executive Officer, Director
Next action: Open filing details

4 SNDX

Syndax Pharmaceuticals Inc

Report period: 10 Feb 2025
Transactions: 1
Transaction value: -$206,017
Accepted by SEC: 12 Feb 2025, 17:15
Role: Chief Executive Officer, Director
Next action: Open filing details

4 SNDX

Syndax Pharmaceuticals Inc

Report period: 05 Feb 2025
Transactions: 3
Transaction value: +$5,332,600
Accepted by SEC: 07 Feb 2025, 16:42
Role: Chief Executive Officer, Director
Next action: Open filing details

4 PYXS

Pyxis Oncology, Inc.

Report period: 10 Jun 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 10 Jun 2024, 17:31
Role: Director
Next action: Open filing details

3 PYXS

Pyxis Oncology, Inc.

Report period: 10 Jun 2024
Transactions: 0
Transaction value: $0
Accepted by SEC: 10 Jun 2024, 17:26
Role: Director
Next action: Open filing details

4 SNDX

Syndax Pharmaceuticals Inc

Report period: 07 Feb 2024
Transactions: 3
Transaction value: +$4,779,060
Accepted by SEC: 09 Feb 2024, 16:05
Role: Chief Executive Officer, Director
Next action: Open filing details

4

CTI BIOPHARMA CORP

Report period: 26 Jun 2023
Transactions: 6
Transaction value: $0
Accepted by SEC: 26 Jun 2023, 16:05
Role: Director
Next action: Open filing details

4

CTI BIOPHARMA CORP

Report period: 05 Apr 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 07 Apr 2023, 18:22
Role: Director
Next action: Open filing details

4 SNDX

Syndax Pharmaceuticals Inc

Report period: 06 Feb 2023
Transactions: 3
Transaction value: -$291,376
Accepted by SEC: 08 Feb 2023, 15:49
Role: Chief Executive Officer, Director
Next action: Open filing details

4 SNDX

Syndax Pharmaceuticals Inc

Report period: 02 Feb 2023
Transactions: 1
Transaction value: +$11,705,500
Accepted by SEC: 03 Feb 2023, 16:02
Role: Chief Executive Officer, Director
Next action: Open filing details

4

CTI BIOPHARMA CORP

Report period: 08 Nov 2022
Transactions: 7
Transaction value: -$424,047
Accepted by SEC: 10 Nov 2022, 15:54
Role: Director
Next action: Open filing details

4 SNDX

Syndax Pharmaceuticals Inc

Report period: 06 Oct 2022
Transactions: 3
Transaction value: -$268,162
Accepted by SEC: 07 Oct 2022, 16:05
Role: Chief Executive Officer, Director
Next action: Open filing details

4 SNDX

Syndax Pharmaceuticals Inc

Report period: 30 Sep 2022
Transactions: 9
Transaction value: -$548,736
Accepted by SEC: 04 Oct 2022, 17:49
Role: Chief Executive Officer, Director
Next action: Open filing details

4 SNDX

Syndax Pharmaceuticals Inc

Report period: 25 Jul 2022
Transactions: 6
Transaction value: -$463,772
Accepted by SEC: 27 Jul 2022, 18:42
Role: Chief Executive Officer, Director
Next action: Open filing details

4

CTI BIOPHARMA CORP

Report period: 07 Jul 2022
Transactions: 6
Transaction value: -$130,995
Accepted by SEC: 11 Jul 2022, 16:51
Role: Director
Next action: Open filing details

4 SNDX

Syndax Pharmaceuticals Inc

Report period: 06 Jul 2022
Transactions: 6
Transaction value: -$222,012
Accepted by SEC: 08 Jul 2022, 17:51
Role: Chief Executive Officer, Director
Next action: Open filing details

4

CTI BIOPHARMA CORP

Report period: 05 Jul 2022
Transactions: 6
Transaction value: -$479,107
Accepted by SEC: 07 Jul 2022, 17:02
Role: Director
Next action: Open filing details

4

CTI BIOPHARMA CORP

Report period: 09 Mar 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 11 Mar 2022, 18:43
Role: Director
Next action: Open filing details

4 SNDX

Syndax Pharmaceuticals Inc

Report period: 02 Feb 2022
Transactions: 1
Transaction value: +$5,131,750
Accepted by SEC: 03 Feb 2022, 16:33
Role: Chief Executive Officer, Director
Next action: Open filing details

4 SNDX

Syndax Pharmaceuticals Inc

Report period: 16 Dec 2021
Transactions: 12
Transaction value: -$1,050,501
Accepted by SEC: 20 Dec 2021, 17:44
Role: President and COO, Director
Next action: Open filing details

4 SNDX

Syndax Pharmaceuticals Inc

Report period: 13 Dec 2021
Transactions: 6
Transaction value: -$462,276
Accepted by SEC: 15 Dec 2021, 16:35
Role: President and COO, Director
Next action: Open filing details

4 SNDX

Syndax Pharmaceuticals Inc

Report period: 25 Oct 2021
Transactions: 6
Transaction value: -$728,960
Accepted by SEC: 27 Oct 2021, 16:11
Role: President and COO, Director
Next action: Open filing details

4 SNDX

Syndax Pharmaceuticals Inc

Report period: 27 Sep 2021
Transactions: 3
Transaction value: -$300,885
Accepted by SEC: 28 Sep 2021, 16:36
Role: President and COO, Director
Next action: Open filing details

4 SNDX

Syndax Pharmaceuticals Inc

Report period: 20 Sep 2021
Transactions: 9
Transaction value: -$439,607
Accepted by SEC: 22 Sep 2021, 16:50
Role: President and COO, Director
Next action: Open filing details

4 SNDX

Syndax Pharmaceuticals Inc

Report period: 13 Sep 2021
Transactions: 6
Transaction value: -$726,833
Accepted by SEC: 15 Sep 2021, 16:16
Role: President and COO, Director
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .